Updated time: 2020-09-01 15:09:57
12T-1090821
2020-09-01
Know-how
In this invention, a recombinant vaccine comprising residues 319-541 of the Spike-RBD is formulated in ASD25X nanocomplex adjuvant for applying to the development of COVID-19 vaccine. The S-RBD formulated in ASD25X (ASD25X-RBD) induces high levels of serum anti-RBD antibody in the immunized mice, as compared with the S-RBD (Alum-RBD) formulated in alum. The sera from the immunized mice contained high titers of neutralizing antibodies and can prevented SARS-CoV-2 infection in cell-based assay. In a mouse model expressing human ACE-2 (delivered by AAV/hACE2), ASD25X-RBD showed high immunogenicity and neutralizing capacities which correlated with protective efficacy in mice. These results demonstrate ASD25X-RBD could be a potential vaccine candidate for preventing COVID-19 disease.
- No infectious virus needs to be handled
- High human safety
- Easy production and commercial application
- ASD25X adjuvants can be used to increase immunogenicity
- SARS-CoV-2 vaccine development
Tao, Mi-Hua
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Development of COVID-19 ASD25X-RBD recombinant protein vaccine